Berlin, Germany
Berlin, Germany

Time filter

Source Type

Partnering with Medical Education Resources for comprehensive medical use training for physicians, pharmacists, registered nurses, and health care professionals Healthway Education Systems, a nationally and internationally accredited medical cannabis training platform, in joint partnership with Cannabis World Congress and Business (CWCB), will provide Comprehensive Medical Cannabis and Cannabinoid Training during the Cannabis World Congress and Business Exposition (CWCBExpo). On Wednesday, June 14, 2017, the training is designed to meet the educational needs of physicians, pharmacists, registered nurses, health care professionals and the public involved in the care of patients. Dr. Greg Smith, MD, and Dr. Kevin Smith, MD, will address the distinctions and practicalities of medical cannabis use. The live, accredited Comprehensive Medical Cannabis and Cannabinoid Training workshop will educate medical practitioners, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists as well as industry professionals, on the advanced basic and clinical science of cannabinoids and medical cannabis. This activity is jointly provided by Medical Education Resources and Healthway Education Systems. Dr. Greg Smith is Chief Medical Advisor for Michael James Enterprises, Inc. He earned his medical degree from Rush Medical School in Chicago and a Masters of Public Health from Harvard University. He completed residency training in Preventive Medicine at Walter Reed Army Medical Center. Since leaving the U.S. Army with the rank of Major, Dr. Smith has practiced in California, Georgia and Florida for the past 25 years. He first trained on use of medical cannabis in California in 2000 and has made medical cannabis and CBD oil part of his practice since that time. An avid writer, Dr. Smith has published two medical textbooks (including the first science-based textbook on medical cannabis, "Medical Cannabis: Basic Science & Clinical Applications"), a novel titled "Malpractice," and articles with many magazines and over a dozen peer-reviewed medical publications. He is active in promoting research on medical cannabis and neurodegenerative conditions such as Alzheimer's disease, post-concussion dementia and Huntington's disease. After completing his medical degree, Dr. Kevin Smith received a Masters of Public Health from Yale University and completed his residency in Occupational and Preventive Medicine at both Yale and the University of Iowa. His 30-plus years’ experience included serving his country in the U.S. Army Reserve Medical Corps, where he reached the rank of Lieutenant Colonel and was deployed several times as a Field Surgeon and Preventive Medicine Physician. Fluent in Spanish and having lived in many locations worldwide, including the U.K., Sweden, Mexico and the Dominican Republic, Dr. Smith has also been on the teaching faculties of several universities and institutes. His ability to educate a variety of medical personnel including physicians, nurse practitioners and physician assistants alike has garnered wide respect for both technical and practical knowledge. Switching easily between patient one-on-one, lecturing, reviews and consulting, Dr. Smith’s dedicated commitment to being a physician who helps others is evident to all those who meet him. This activity has been designed to meet the educational needs of physicians, pharmacists, registered nurses, healthcare professionals, and the public involved in the care of patients. World-class educators will address the distinctions and practicalities of medical cannabis use. Healthway Education Systems specializes in certified competency training and accredited education for healthcare providers, administrators, patients and cannabis industry professionals. Their educational resources are designed to meet the educational needs of physicians, pharmacists, registered nurses, healthcare professionals, and the public involved in the care of patients. Peer-to-peer instruction addresses the distinctions and practicalities of medical cannabis use. This activity has been approved for: Training will be held June 14 (9 a.m.-5 p.m.), during the Cannabis World Congress at the Jacob J. Javits Convention Center, 655 W. 34th St., Hall 1A, New York, NY 10001. The cost is $399, and registration begins at 8:00 a.m. For CME and to register for Healthway Education Systems seminar today, visit https://cwcbexpo.healthwayeducation.com/ Healthway Education Systems bridges that gap between the healthcare professional and responsible patient care. For events or press inquiries, please contact media relations liaison Dana Blickensderfer at dana@healthwayeducation.com or call 813-775-7107, or contact Dana Cobb at Dana@TrizCom.com or call 972-955-9747. About Healthway Education Systems Healthway Education Systems is the premier industry leader in Accredited Medical Cannabis Education, both nationally and internationally. Healthway Education Systems specializes in Certified Training and Accredited Education for healthcare providers, administrators, patients, and cannabis industry professionals. Physician Credit: This activity has been approved for AMA PRA Category 1 Credit(s)TM. Nursing Credit: Nursing contact hours will be provided for this activity. Pharmacy Credit: Pharmacy credit (CEUs) will be designated for this activity.


News Article | May 12, 2017
Site: co.newswire.com

Partnering with Medical Education Resources for comprehensive medical use training for physicians, pharmacists, registered nurses, health care professionals. Healthway Education Systems, a nationally and internationally accredited medical cannabis training platform, in joint providership with Medical Education Resources, will provide Comprehensive Medical Cannabis and Cannabinoid Training at the Northeastern Institute of Cannabis on Saturday, June 24, 2017. The training is designed to meet the educational needs of physicians, pharmacists, registered nurses, health care professionals and the public involved in the care of patients. Dr. Greg Smith and Dr. Kevin Smith will address the distinctions and practicalities of medical cannabis use. On Friday, June 23, Healthway Education Systems will also provide a Cannabis 101 course, which will include Cannabis Products Training by Trichome Institute, Healthway's education partner. Advisor Mark Mersman will be speaking at this event, providing information on medical cannabis fundamentals. Dr. Greg Smith is Chief Medical Advisor for Michael James Enterprises, Inc. He earned his medical degree from Rush Medical School in Chicago and a Masters of Public Health from Harvard University. He completed residency training in Preventive Medicine at Walter Reed Army Medical Center. Since leaving the U.S. Army with the rank of Major, Dr. Smith has practiced in California, Georgia and Florida for the past 25 years. He first trained on use of medical cannabis in California in 2000 and has made medical cannabis and CBD oil part of his practice since that time. An avid writer, Dr. Smith has published two medical textbooks (including the first science-based textbook on medical cannabis "Medical Cannabis: Basic Science & Clinical Applications"), a novel titled Malpractice, and articles with many magazines and over a dozen peer-reviewed medical publications. He is active in promoting research on medical cannabis and neurodegenerative conditions such as Alzheimer's disease, post-concussion dementia and Huntington's disease. After completing his medical degree, Dr. Kevin Smith received a Masters of Public Health from Yale University and completed his residency in Occupational and Preventive Medicine at both Yale and the University of Iowa. His 30 plus years’ experience included serving his country in the U.S. Army Reserve Medical Corps, where he reached the rank of Lieutenant Colonel and was deployed several times as a Field Surgeon and Preventive Medicine Physician. Fluent in Spanish and having lived in many locations worldwide including the U.K., Sweden, Mexico and the Dominican Republic, Dr. Smith has also been on the teaching faculties of several universities and institutes. His ability to educate a variety of medical personnel including physicians, nurse practitioners and physician assistants alike has garnered wide respect for both technical and practical knowledge. Switching easily between patient one-on-one, lecturing, reviews and consulting, Dr. Smith’s dedicated commitment to being a physician who helps others is evident to all those who meet him. Mark is joining the Heathway team in the capacity of strategic advisor. As a serial entrepreneur, Mark has led several teams through the start-up phase and brings 10 years of experience in operations and finance. Since 2008, as a co-founder and President of Unity Resources, LLC and Legacy Income Properties, LLC, Mr. Mersman has been leading a team in evaluating and investing in minerals and royalties for families and institutions. Mark has formed and managed over 10 private investment funds, altogether encompassing over $10 million and in excess of 100 mineral and royalty acquisitions and divestitures. Mr. Mersman was the founder and President of Mersman Capital Management, Inc., a private wealth advisory firm formed in September 2007 that provided portfolio management for a small group of high net worth individuals. Mersman Capital Management’s portfolio was successfully sold and transitioned to another advisory firm in December of 2015. Prior to forming Mersman Capital Management, Mark served as Regional Vice President for Fisher Investments from April 2000 to September 2007, where he managed a combined client portfolio of representing over $200 million. Mr. Mersman has previously held FINRA licenses 7, 63, and 65, and held the designation of Chartered Retirement Planning Counselor. Mark is a graduate with a B.B.A. in Marketing and Finance from the University of Arkansas. Healthway Education Systems specializes in certified competency training and accredited education for health care providers, administrators, patients and cannabis industry professionals. Medical Education Resources is accredited by: This activity has been approved for: Training will be held Saturday, June 24, (9 a.m.-5 p.m.), at the Northeastern Institute for Cannabis, 10 Tech Circle, Natick, MA 01760. The cost is $397. For CME information and to register, visit www.HealthwayEducation.com The Cannabis 101 course will be held on Friday, June 23, (5 p.m.- 9 p.m.), at the same location. The cost is $79. Register for Healthway Education Systems seminar today or for CME information, visit https://www.healthwayeducation.com/events/boston/ About Healthway Education Systems Healthway Education Systems is a nationally and internationally accredited medical cannabis training platform. The Healthway model is an educational program designed specifically to deliver state-of-the-art, medical cannabis education to medical, health care and cannabis industry professionals and patients alike. Healthway bridges the gap between state medical marijuana programs, medical education and responsible patient care. The company’s mission is to give health care and public service professionals the competence and confidence to educate their patients and students on safety as well as healthier and more effective treatment options that patients, families and communities can use to improve their quality of life. For more information, please visit www.healthwayeducation.com


News Article | May 11, 2017
Site: co.newswire.com

Partnering with Medical Education Resources for comprehensive medical use training for physicians, pharmacists, registered nurses, health care professionals Healthway Education Systems, a nationally and internationally accredited medical cannabis training platform, in joint providership with Medical Education Resources, will deliver Comprehensive Medical Cannabis and Cannabinoid Training at the Southeast Cannabis Conference on Friday, June 9, 2017. The training is designed to meet the educational needs of physicians, pharmacists, registered nurses, health care professionals and the public involved in the care of patients. Dr. Greg Smith and Dr. Kevin Smith will address the distinctions and practicalities of medical cannabis use. Dr. Greg Smith is Chief Medical Advisor for Michael James Enterprises, Inc. He earned his medical degree from Rush Medical School in Chicago and a Masters of Public Health from Harvard University. He completed residency training in Preventive Medicine at Walter Reed Army Medical Center. Since leaving the U.S. Army with the rank of Major, Dr. Smith has practiced in California, Georgia and Florida for the past 25 years. He first trained on use of medical cannabis in California in 2000 and has made medical cannabis and CBD oil part of his practice since that time. An avid writer, Dr. Smith has published two medical textbooks (including the first science-based textbook on medical cannabis "Medical Cannabis: Basic Science & Clinical Applications"), a novel titled "Malpractice," and articles with many magazines and over a dozen peer-reviewed medical publications. He is active in promoting research on medical cannabis and neurodegenerative conditions such as Alzheimer's disease, post-concussion dementia and Huntington's disease. After completing his medical degree, Dr. Kevin Smith received a Masters of Public Health from Yale University and completed his residency in Occupational and Preventive Medicine at both Yale and the University of Iowa. His 30-plus years’ experience included serving his country in the U.S. Army Reserve Medical Corps, where he reached the rank of Lieutenant Colonel and was deployed several times as a Field Surgeon and Preventive Medicine Physician. Fluent in Spanish and having lived in many locations worldwide, including the U.K., Sweden, Mexico and the Dominican Republic, Dr. Smith has also been on the teaching faculties of several universities and institutes. His ability to educate a variety of medical personnel including physicians, nurse practitioners and physician assistants alike has garnered wide respect for both technical and practical knowledge. Switching easily between patient one-on-one, lecturing, reviews and consulting, Dr. Smith’s dedicated commitment to being a physician who helps others is evident to all those who meet him. Healthway Education Systems specializes in certified competency training and accredited education for health care providers, administrators, patients and cannabis industry professionals. Medical Education Resources is accredited by: This activity has been approved for: Training will be held Friday, June 9, (9 a.m.-5 p.m.), during the Southeast Cannabis Conference at the Greater Fort Lauderdale-Broward County Convention Center, 1950 Eisenhower Blvd., Fort Lauderdale, FL 33316. The cost is $397. Healthway Education Systems is also providing a $79 Cannabis 101 Non-Accredited Conference. Register for Healthway Education Systems seminar today or for CME information, visit https://secc.healthwayeducation.com/ About Healthway Education Systems Healthway Education Systems is the Premier industry leader in Accredited Medical Cannabis Education both Nationally and Internationally. Healthway Education Systems specializes in Certified Training and Accredited Education for healthcare providers, administrators, patients, and cannabis industry professionals. Physician Credit: This activity has been approved for AMA PRA Category 1 Credit(s)TM. Nursing Credit: Nursing contact hours will be provided for this activity. Pharmacy Credit: Pharmacy credit (CEUs) will be designated for this activity.


News Article | May 17, 2017
Site: www.eurekalert.org

LOS ANGELES (May 17, 2017) -- A Cedars-Sinai-led team of investigators has successfully repaired severe limb fractures in laboratory animals with an innovative technique that cues bone to regrow its own tissue. If found to be safe and effective in humans, the pioneering method of combining ultrasound, stem cell and gene therapies could eventually replace grafting as a way to mend severely broken bones. "We are just at the beginning of a revolution in orthopedics," said Dan Gazit, PhD, DMD, co-director of the Skeletal Regeneration and Stem Cell Therapy Program in the Department of Surgery and the Cedars-Sinai Board of Governors Regenerative Medicine Institute. "We're combining an engineering approach with a biological approach to advance regenerative engineering, which we believe is the future of medicine." Gazit was the principal investigator and co-senior author of the research study, published in the journal Science Translational Medicine. More than 2 million bone grafts, frequently necessitated by severe injuries involving traffic accidents, war or tumor removal, are performed worldwide each year. Such injuries can create gaps between the edges of a fracture that are too large for the bone to bridge on its own. The grafts require implanting pieces from either the patient's or a donor's bone into the gap. "Unfortunately, bone grafts carry disadvantages," said Gazit, a professor of surgery at Cedars-Sinai. "There are huge unmet needs in skeleton repair." One problem is that enough healthy bone is not always available for repairs. Surgeries to remove a bone piece, typically from the pelvis, and implant it can lead to prolonged pain and expensive, lengthy hospitalizations. Further, grafts from donors may not integrate or grow properly, causing the repair to fail. The new technique developed by the Cedars-Sinai-led team could provide a much-needed alternative to bone grafts. In their experiment, the investigators constructed a matrix of collagen, a protein the body uses to build bones, and implanted it in the gap between the two sides of a fractured leg bone in laboratory animals. This matrix recruited the fractured leg's own stem cells into the gap over a period of two weeks. To initiate the bone repair process, the team delivered a bone-inducing gene directly into the stem cells, using an ultrasound pulse and microbubbles that facilitated the entry of the gene into the cells. Eight weeks after the surgery, the bone gap was closed and the leg fracture was healed in all the laboratory animals that received the treatment. Tests showed that the bone grown in the gap was as strong as that produced by surgical bone grafts, said Gadi Pelled, PhD, DMD, assistant professor of surgery at Cedars-Sinai and the study's co-senior author. "This study is the first to demonstrate that ultrasound-mediated gene delivery to an animal's own stem cells can effectively be used to treat nonhealing bone fractures," Pelled said. "It addresses a major orthopedic unmet need and offers new possibilities for clinical translation." The study involved six departments at Cedars-Sinai, plus investigators from Hebrew University in Jerusalem; the University of Rochester in Rochester, New York; and the University of California, Davis. "Our project demonstrates how scientists from diverse disciplines can combine forces to find solutions to today's medical challenges and help develop treatments for the patients of tomorrow," said Bruce Gewertz, MD, surgeon-in-chief and chair of the Department of Surgery at Cedars-Sinai. Research reported in this publication was supported by grants from the California Institute for Regenerative Medicine under award number TR4-06713; the National Institutes of Health under award numbers R01CA112356 and P30AR069655; the IDF Medical Corps; and the Milgrom Family. Competing interests: Gadi Pelled, Dan Gazit and Zulma Gazit are shareholders in GamlaStem Medical Inc., which did not provide funds for this study. A patent application related to the study's findings is pending.


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company”, “Alliance”, “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that Gregg Alan Dickerson, M.D., FACR, FACRO, has joined Alliance Cancer Centers in Greenville and Clarksdale and will be offering radiation oncology services to patients throughout Greenville, Clarksdale and the surrounding communities. “We are pleased to have Dr. Dickerson join the medical staff of the Alliance Cancer Centers in Greenville and Clarksdale,” said Candi Underwood, Site Administrator for the Alliance Cancer Centers in Greenville and Clarksdale. “Dr. Dickerson is a highly accomplished physician who brings over thirty years of radiation oncology experience to our cancer care treatment team and we are fortunate to have him care for the patients in our centers.” Gregg Alan Dickerson, M.D., FACR, FACRO, is a board certified radiation oncologist. Dr. Dickerson received his Bachelor of Arts with a double major in chemistry and biology from Indiana University in Bloomington, Indiana, and his medical degree from Indiana University School of Medicine in Indianapolis, Indiana. He completed his residency training in radiation oncology at the Bodine Center for Cancer Treatment at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also served as Chief Resident. In addition to his education and medical training, Dr. Dickerson spent 11 years serving our country as a flight surgeon in the Medical Corps of the Air National Guard, becoming a Major before being honorably discharged in 1996. Dr. Dickerson joined the Alliance Cancer Centers in Greenville and Clarksdale last October as an interim physician. “After many rewarding and productive years in Denver, Colorado, where I became highly specialized and accomplished for my work treating prostate cancer with radiosurgery, it was time to get ready for the next phase of my career,” said Dickerson. “It was at that time colleagues in the leadership of Alliance Oncology encouraged me to come to Mississippi to spend some time helping the good people of the Delta. What started off as a commitment for just a few months turned into a desire to continue caring for the dear people here and face the challenges that the spectrum of cancers they develop present. Joining the many other very compassionate physicians in the Delta and employing my advanced skills has been extremely satisfying and ultimately led to wanting to continue my work here.” Dr. Dickerson has been awarded over ten specialty honors and peer selected honors, including being ranked the number one radiation oncologist in Colorado in 2014 by HealthGrades.com. He also holds both military and civilian honors. He is a member of the American Society of Therapeutic Radiologists and Oncologists (ASTRO), the American College of Radiology (ACR), the American College of Radiation Oncology (ACRO), the Colorado Radiological Society, and the CyberKnife Society. For more information on Dr. Dickerson, or to schedule an appointment, please visit www.alliance-greenville-clarksdale.com. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.


News Article | November 16, 2016
Site: www.24-7pressrelease.com

JACKSON, MS, November 16, 2016-- Dr. Richard D. deShazo has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Dr. deShazo's busy career has included service as a practicing medical consultant, educator, researcher and academic administrator; public broadcasting producer and on air host; and author. Born in Birmingham, Ala. in 1945, he earned a Bachelor of Arts in chemistry and religion from Birmingham Southern College before attaining an MD at the University of Alabama in 1971. Dr. deShazo then completed an internship in pediatrics, a residency in internal medicine, a fellowship in immunology and microbiology, and a fellowship in clinical immunology. He further prepared for his career by becoming board-certified by the American Board of Internal Medicine, the American Board of Allergy and Immunology, the American Board of Rheumatology, the American Board of Geriatrics and the National Board of Medical Examiners. He has published over 300 original scientific articles in peer reviewed literature.Having completed a residency and fellowships at the Walter Reed Army Medical Center, Dr. deShazo spent eight years in the U.S. Army Medical Corps reaching the rank of lieutenant colonel. He was awarded the Distinguished Service Medal by the Department of the Army. He also began his career as a medical educator, starting as a clinical assistant professor of medicine at the University of Colorado School of Medicine. He was then an assistant professor of medicine and pediatrics at the Uniformed Services University of the Health Sciences before spending nine years with Tulane University School of Medicine. While at Tulane, Dr. deShazo advanced from associate professor to full professor of medicine and pediatrics, and also served as vice chair of clinical operations. In 1989, he left Tulane University to become a professor and chairman of the Department of Medicine at the University of South Alabama College of Medicine. After eight years in this role, he accepted the position of professor of medicine and pediatrics and chairman of the Department of Medicine at the University of Mississippi Medical Center. He stepped down from his chairman role in 2010, but he continues to teach at the university as a Billy S. Guyton Distinguished Professor of medicine and pediatrics.In addition to teaching, Dr. deShazo has been a producer of radio and television health documentary programming for Mississippi Public Broadcasting since 2010. As such, he leads a daily radio series called "Southern Remedy," during which experts discuss current and relevant health issues and topics. The program can be heard on Mississippi Public Broadcasting's Think Radio from 11 am until noon, as well as online at http://www.mpbonline.org/programs/radio/listen-live . He was associate editor of the Southern Medical Journal from 1995 to 2013. He now serves as an associate editor of the American Journal of Medicine and is on the editorial boards of numerous medical journals.Dr. deShazo has remained an active member of the medical community through affiliations with the American College of Physicians, the American College of Rheumatology, the American College of Chest Physicians, and the American Academy of Allergy, Asthma and Immunology, among numerous other organizations. He was elected a Master of the American College of Physicians and a Distinguished Fellow of the American College of Allergy, Asthma and Immunology. He has taken on a number of leadership roles within these organizations and has received formal honors from them as well. Some of his most recent honors include a 2015 Southeast Emmy Award nomination and a 2015 and 2016 Telly Award for his work on "Southern Remedy." In 2013, he received the Mississippi Humanities Council Commercial Media Award, as well as media and communication awards from the Association of American Medical Colleges. He also received the Martha Meyers Physician Role Model Award from the University of Alabama School of Medicine. Dr. deShazo and his wife, Gloria, have 3 children and 6 grandchildren. Dr. deShazo has been featured in the 59th through 70th editions of Who's Who in America, the 7th and 8th editions of Who's Who in American Education, the 2nd through 8th editions of Who's Who in Medicine and Healthcare, the 11th and 12th editions of Who's Who in Science and Engineering, the 27th through 42nd editions of Who's Who in the South and Southwest, and the 26th through 33rd editions of Who's Who in the World.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com


Gross R.,Myers JDC Brookdale Institute | Gross R.,Bar - Ilan University | Brammli-Greenberg S.,Myers JDC Brookdale Institute | Rabinowitz J.,Bar - Ilan University | And 3 more authors.
International Journal of Pediatric Obesity | Year: 2011

Objective. To analyze the temporal trends of obesity over time among male adolescents of different ethnic origins. Methods. Population-based national data of subjects presenting at recruitment centers for medical examinations as part of screening for military draft. Subjects were 17-year-old Jewish males (n=1 140 937) born in the years 19501986. Data on body mass index (BMI) were measured (without clothing and shoes) by physicians. We calculated the prevalence of obesity (BMI 29.4 or higher) for each year by ethnic origin group. A Multinomial logistic regression model was used to estimate the effects of ethnic origin and other risk factors on the likelihood of obesity. Results. Over time, obesity rates have risen among all ethnic groups of adolescents. Multinomial regression analysis showed a lower likelihood of obesity among those of Asia-Africa origin as compared with other groups. However, obesity rates have increased more significantly over time among this ethnic group compared with the other groups. Conclusion. A significant finding of this study is the disparities in temporal trends in the likelihood of obesity over time. Among adolescents of Asia-Africa origin the likelihood of obesity increased more steeply over time compared with other groups of adolescents. Health services in Israel should thus consider Asia-African origin as a distinct risk factor and target interventions to prevent future obesity among these adolescents. © 2011 Informa Healthcare.


YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in the management of burns in mass casualty incidents was selected as “Best Poster” at the International Disaster and Military Medicine (DiMiMED) 4th Annual Conference, held November 15-16 in Dusseldorf, Germany. The poster, titled “The role of rapid & effective enzymatic debridement/escharotomy in burn mass casualties' incidents,” was delivered by Prof. Lior Rosenberg, MediWound's Chief Medical Officer and former head of the International Society of Burn Injury disaster committee.  The prize was awarded by the co-chairmen of the conference, Dr. Christoph Büttner, MC Dr, Rear Admiral uh (ret), Editor-in-chief of Medical Corps International Forum, Germany and Dr. Rob van der Meer, MD, Brigadier General (ret), Former Surgeon General of the Netherlands Armed Forces. The poster highlights how NexoBrid's debridement and enzymatic escharotomy can reduce surgical burden, dependency on highly trained surgeons and scarce surgical facilities.  NexoBrid provides rapid and selective, nonsurgical removal of the eschar at the patient's bedside, resolves or possibly prevents Burn Induced Compartment Syndrome (BICS), which currently requires immediate surgical intervention, and enables early visual diagnosis of burn severity.  Collectively these contribute to increased surge capacity, and possibly reduced mortality and morbidity as well as faster resilience. “We are delighted that the role of NexoBrid in the management of mass casualty incidents continues to be acknowledged by thought-leading organizations such as the DiMiMED and the International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters.  Recognition has also come from important government agencies and officials such as the U.S. Biomedical Advanced Research and Development Authority and the president and government officials of Romania, following the Colectiv nightclub disaster,” noted Gal Cohen, President and Chief Executive Officer of MediWound. "Unfortunately, mass casualty incidents are not limited to acts of war or urban terror. There are civilian mass casualties as we have seen recently with the explosions at a Chinese chemical plant, and at an amusement park in Taiwan, each of which resulted in hundreds of burn victims. Even a multivehicle road accident could challenge burn treatment capacity and turn into a mass casualty incident. We look forward to working with various international agencies and with governments to advance the use of NexoBrid for mass casualty and disaster preparedness, as well as in military medicine,” added Mr. Cohen. According to Prof. Rosenberg, "Burn Induced Compartment Syndrome is characterized by severe high pressure in the compartment, which results in insufficient blood supply to muscles and nerves. It is a medical emergency that requires immediate surgical intervention. On one hand, if left untreated, the lack of blood supply leads to permanent muscle and nerve damage and can result in the loss of limb function.  On the other hand, if escharotomy is not done by highly trained personnel, it could result in permanent damage to vital structures such as nerves and tendons, leading to impaired long-term functionality and permanent long linear scars. “During the NexoBrid Phase 3 study, no escharotomies were done in deeply burned hands treated with NexoBrid, versus 9.8% in deeply burned hands treated by standard of care. In fact, during NexoBrid’s clinical development more than 130 extremities treated with NexoBrid did not require escharotomies,” added Prof. Rosenberg. “This is imperative in the management of mass casualty incidents as extremities are the most frequently burned area, and if deeply burned are most likely to develop BICS. Not only can NexoBrid rapidly remove eschar and allow burn severity diagnosis, but it may avoid the need for immediate escharotomy. It is important to note that in routine burn care as well, surgical debridement and escharotomy are among the most traumatic surgical procedures and are challenging for both the care provider and patient. As demonstrated, NexoBrid nonsurgical debridement can significantly reduce such surgical burden.” DiMiMED is the  International Conference on Disaster and Military Medicine focussing on current issues in military medicine and disaster medicine. The disasters taking place all over the world have shown that it is absolutely essential for civilian medical services and the military medical services to join forces to provide optimum on-site medical care. In addition to civilian medical services, the medical services of the armed forces are increasingly used to deal with disasters. DiMiMED provides a platform for exchanging experiences, holding discussions and for promoting global cooperation. The DiMiMED conference is organized by the Beta Group / Beta Verlag & Marketinggesellschaft mbH, under the auspices of the Medical Corps International Forum and powered by MEDICA / Messe Düsseldorf GmbH. NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues.  NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe and Israel and will be launched in Argentina in the coming months. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®.  In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.   For more information, please visit www.mediwound.com. This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2015 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.


News Article | November 17, 2016
Site: co.newswire.com

The Israel Defense Forces (IDF) Medical Corps received the first “Type 3” designation by the United Nations’ World Health Organization (WHO). At a ceremony last week, the Israeli field hospital, comprised of 30 medical shelters from Alaska Structures Inc., was described as “the number one in the world”. In the wake of a sudden onset disaster (SOD), the Type 3 designation will ensure the Israeli medical team and field hospital will continue to be the first allowed on the scene to provide emergency medicine and services. To earn the Type 3 designation, the IDF’s field hospital must have 40 inpatient beds, two operating rooms capable of performing 15 to 30 surgeries per day, and provide other services such as rehabilitation. The IDF field hospital far surpasses the Type 3 requirement, technically making it a “Type 3 Plus” system - is equipped with 86 inpatient beds, four operating rooms, and has the ability to carry out plastic surgery and OB/GYN care. 16 foreign medical teams (FMTs) have been awarded Type 1 or Type 2 designations by the WHO. The IDF Medical Corps is the only medical team and field hospital, with a military component to have been awarded the Type 3 designation. There are currently no other Type 3 classifications in the process of being verified, stated Dr. Ian Norton, the lead author of the classification system and Head of the WHO delegation. It is a “national treasure” that has the capabilities of an advanced, permanent hospital but can be setup almost anywhere in under 12 hours, stated its commander, Lt. Col. (res.) Dr. Ofer Merin. A formal ceremony being held in Hong Kong at the end of the month will award the IDF Medical Corps members with special patches. Helping other countries in need is “the most effective kind of diplomacy” stated former foreign minister Avigdor Liberman. Since 1999, Alaska Structures has provided more than 35,000 American-made military shelters and over 17,000 Environmental Control Units (ECU) to U.S. and other; Military Forces around the world.

Loading Medical Corps collaborators
Loading Medical Corps collaborators